Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): Should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1585-1588

  Massard, C ^a,b   Plantade, A ^a,b   Gross Goupil, M ^a,b   Loriot, Y ^a,b   Besse, B ^a,b   Raynard, B ^a   Blot, F ^a   Antoun, S ^a   Nitenberg, G ^a   Escudier, B ^a,b   Fizazi, K ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

ARDS; Chemotherapy; Germ cell tumours; Nonseminoma

Indexed keywords

BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; VINBLASTINE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; GONADOTROPIN BLOOD LEVEL; HUMAN; HYPOXIA; INCIDENCE; LUNG METASTASIS; MALE; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME; TREATMENT RESPONSE;

EID: 77955261775     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq021     Document Type: Article

References (25)

1. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol 2008; 53(3): 478-496.
2. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53(3): 497-513.
3. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15(2): 594-660.
4. Feldman DR, Bosl GJ, Sheinfeld J et al. Medical treatment of advanced testicular cancer. JAMA 2008; 299(6): 672-684.
5. Kondagunta GV, Motzer RJ. Chemotherapy for advanced germ cell tumors. J Clin Oncol 2006; 24(35): 5493-5502.
6. Fléchon A, Rivoire M, Droz JP. Management of advanced germ-cell tumors of the testis. Nat Clin Pract Urol 2008; 5(5): 262-276.
7. Moran-Ribon A, Droz JP, Leclercq B et al. Super-high risk germ-cell tumors: a clinical entity. Report of eleven cases. Support Care Cancer 1994; 2: 253-258.
8. Bernard G, Artigas A, Brigham KL et al. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcome and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824.
9. Fizazi K, Prow DM, Do KA et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 2002; 86(10): 1555-1560.
10. Logothetis CJ. Choriocarcinoma syndrome. Cancer Bull 1984; 36: 118-120.
11. Kirch C, Blot F, Fizazi K et al. Acute respiratory distress syndrome after chemotherapy for lung metastases from non-seminomatous germ-cell tumors. Support Care Cancer 2003; 11(9): 575-580.
12. Bosl GJ, Geller NL, Bajorin et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988; 6(8): 1231-1238.
13. Droz JP, Kramar A, Biron P et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007; 51(3): 739-746: discussion 747-748.
14. Logothetis CJ, Samuels ML, Selig DE et al. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med 1986; 81(2): 219-228.
15. Fizazi K, Do KA, Wang X et al. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol 2002; 13(1): 125-134.
16. Phipps JH, Madden FJ, Shaw PA. Fatal respiratory failure following chemotherapy of advanced teratoma-a pulmonary tumour lysis syndrome? Lancet 1985; 1(8444): 1505.
17. Schnorrer M, Ondrus D, Cársky S et al. Management of germ cell testicular cancer with pulmonary metastases. Neoplasma 1996; 43(1): 47-50.
18. Blayney DW, Goldberg DA, Leong LA et al. High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. Cancer 1993; 71(7): 2351-2357.
19. Kawai K, Takaoka E, Naoi M et al. A case of metastatic testicular cancer complicated by tumour lysis syndrome and choriocarcinoma syndrome. Jpn J Clin Oncol 2006; 36(10): 665-667.
20. Blanke CD, Hemmer MP, Witte RS. Acute tumor lysis syndrome with choriocarcinoma. South Med J 2000; 93(9): 916-919.
21. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25(3): 247-256.
22. Culine S, Kramar A, Théodore C et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate-and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008; 26(3): 421-427.
23. Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 1998; 16(4): 1294-1297.
24. Viglietto G, Romano A, Maglione D et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996; 13(3): 577-587.
25. Collette L, Sylvester RJ, Stenning SP et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999; 91(10): 839-846.